Nabilone for the Treatment of Pain in Fibromyalgia

Journal of Pain

Volumn 9, Issue 2, 2008, Pages 164-173

  Skrabek, Ryan Quinlan ^a   Galimova, Lena ^a   Ethans, Karen ^a   Perry, Daryl ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

cannabinoid; fibromyalgia; Nabilone; pain

Indexed keywords

NABILONE; PLACEBO;

ADULT; ANOREXIA; ARTICLE; ATAXIA; BEDTIME DOSAGE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DYSPHONIA; EUPHORIA; FIBROMYALGIA; FOLLOW UP; HALLUCINATION; HEADACHE; HUMAN; MENTAL CONCENTRATION; NIGHTMARE; ORTHOSTATIC HYPERTENSION; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; VERTIGO; VISUAL ANALOG SCALE; XEROSTOMIA;

ANALGESICS; ANXIETY; DOUBLE-BLIND METHOD; FIBROMYALGIA; HUMANS; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PLACEBOS; QUALITY OF LIFE; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 38349102259     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2007.09.002     Document Type: Article

References (38)

1. Ahles T.A., Khan S.A., Yunus M.B., Spiegell D.A., and Masi A.T. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis and subjects without pain: A blind comparison of DSM-III diagnoses. Am J Psychiatry 148 (1991) 1721-1726
2. Arnold L.M., Hess E.V., Hudson J.I., Welge J.A., Berno S.E., and Keck P.E. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 112 (2002) 191-197
3. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., and Goldstein D.J. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50 (2004) 2974-2984
4. Assefi N.P., Sherman K.J., Jacobsen C., Goldberg J., Smith W.R., and Buchwald D. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. Ann Intern Med 143 (2005) 10-19
5. Bennett R.M., Kamin M., Karim R., and Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. Am J Med 114 (2003) 537-545
6. Buchwald D., and Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities. Arch Intern Med 154 (1994) 2049-2053
7. Burckhardt C.S., Clark S.R., and Bennett R.M. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 18 (1991) 728-733
8. Burstein S., Levin E., and Varanelli C. Prostoglandins and cannabis, II: Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol 22 (1973) 2905-2910
9. Corchero J., Manzanares J., and Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 16 (2004) 159-172
10. Cravatt B.F., and Lichtman A.H. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61 (2004) 149-160
11. Edinger J.D., Wohlgemuth W.K., Krystal A.D., and Rice J.R. Behavioral insomnia therapy for fibromyalgia patients: A randomized clinical trial. Arch Intern Med 165 (2005) 2527-2535
12. Evans F.J. Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Med 57 (1991) S60-S67
13. FDA News. FDA approves first drug for treating fibromyalgia (2007). www.fda.gov/bbs/topics/NEWS/2007/NEW01656.html Accessed April 19, 2007
14. Gibson S.J., Littlejohn G.O., Gorman M.M., Helme R.D., and Granges G. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 58 (1994) 185-193
15. Gilliland R.P. Fibromyalgia. Emedicine (2004). www.emedicine.com/pmr/topic47.htm Accessed April 19, 2007
16. Goldenberg D.L., Burckhardt C., and Crofford L. Management of fibromyalgia syndrome. JAMA 292 (2004) 2388-2395
17. Holman A.J., and Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52 (2005) 2495-2505
18. Ko G., and Wine W. Chronic pain and cannabinoids: A survey study of current fibromyalgia treatment approaches together with an overview and case studies of a new "old" treatment approach. Pract Pain Manage (2005) 1-8
19. Kraj N.J., Norregaard J., Larsen J.K., and Danneskiold-Samsoe B. A blinded controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatrica Scandinavica 89 (1994) 370-375
20. Littlejohn G.O. Balanced treatments for fibromyalgia. Arthritis Rheum 50 (2004) 2725-2729
21. Littlejohn G.O., Weinstein C., and Helme R.D. Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 14 (1987) 1022-1025
22. Mailleux P., and Vanderhaeghen J.J. Delta-9-tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in the caudate-putamen. Eur J Pharmacol 267 (1994) R1-R3
23. Marques A.P., Ferreira E.A.G., Matsutani L.A., Pereira C.A., and Assumpcao A. Quantifying pain threshold and quality of life of fibromyalgia patients. Clin Rheumatol 3 (2005) 266-271
24. Martinez J.E., Ferraz M.B., Fontana A.M., and Atra E. Psychological aspects of Brazilian women with fibromyalgia. J Psychosom Res 39 (1995) 167-174
25. Pertwee R.G. Cannabis and cannabinoids: Pharmacology and rationale for clinical use. Forsch Komplementarmed Suppl 3 (1999) 12-15
26. Price D.D., Bush F.M., Long S., and Hawkins S.W. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain 56 (1994) 217-226
27. Pugh G., Mason D.J., Combs V., and Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55, 940 in the spinal cord. J Pharmacol Exp Ther 281 (1997) 730-737
28. Russo E.B. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuroendocrinol Lett 25 (2004) 31-39
29. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., and Conrath M. CB1-canabinoid and mu-receptor co-localization on postsynaptic target in the rat dorsal horn. NeuroReport 12 (2001) 3689-3692
30. Sayar K., Aksu G., Ak I., and Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37 (2003) 1561-1565
31. Schafer C.F., Brackett D.J., Gunn C.G., and Dubowski K.M. Decreased platelet aggregation following marihuana smoking in man. J Okla State Med Assoc 72 (1979) 435-436
32. Svendsen K.B., Jensen T.S., and Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis?. Randomised double blind placebo controlled crossover trial. BMJ 329 (2004) 253-260
33. Tunks E., McCain G.A., and Hart L.E. The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol 22 (1995) 944-952
34. Wiegant V.M., Sweep C.G., and Nir I. Effect of acute administration of delta 1-tetrahydrocannabinol on beta-endorphin levels in plasma and brain tissue of the rat. Experientia 43 (1987) 413-415
35. Wolfe F., and Cathey M.A. Prevalence of primary and secondary fibrositis. J Rheumatol 10 (1983) 965-968
36. Wolfe F., and Cathey M.A. The epidemiology of tender points. J Rheumatol 12 (1985) 1164-1168
37. Wolfe F., Ross K., Anderson J., Russell I.J., and Herbert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 (1995) 19-28
38. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P., Fam A.G., Farber S.J., Fiechtner J.J., Franklin C.M., Gatter R.A., Hamaty D., Lessard J., Lichtbroun A.S., Masi A.T., and McCain G.A. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 33 (1990) 160-172